Literature DB >> 10536809

[The use of sirdalud in cerebral palsy in children].

I L Brin, A L Kurenkov, V Ia Gotlib.   

Abstract

30 diplegic children (mean age 11.3 +/- 2.8 years old) with severe form of cerebral palsy received sirdalud monotherapy during 2-6 weeks (1 mg for children under 10 years old and 2 mg for older children, 3 times daily). Positive effects were determined in motor, autonomic and mental (emotional) spheres. Sirdalud was also very effective in patients after orthopedic-surgical treatment. Electroneuromyographic analysis showed the decrease of the synergic tonic activity, as well as the improvement of the supraspinal influences and the segmental interaction. Thus, the small doses of sirdalud are effective without side effects in children with cerebral palsy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536809

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  2 in total

1.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 2.  Therapeutic interventions for tone abnormalities in cerebral palsy.

Authors:  Ann H Tilton
Journal:  NeuroRx       Date:  2006-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.